Lupin said today it has acquired Symbiomix Therapeutics for $150 million cash, in a deal designed to expand the buyer’s branded women’s health specialty drug business.
In acquiring Symbiomix through its U.S. subsidiary, Lupin has exercised an option it retained earlier this year to buy the privately held developer of treatments for gynecologic infections.